|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
Clinical Outcome of Cytoreductive Surgery Prior to Bevacizumab for Patients with Recurrent Glioblastoma: A Single-center Retrospective Analysis
| Title: | Clinical Outcome of Cytoreductive Surgery Prior to Bevacizumab for Patients with Recurrent Glioblastoma: A Single-center Retrospective Analysis |
| Authors: | Yamaguchi, Shigeru Browse this author | | Motegi, Hiroaki Browse this author | | Ishi, Yukitomo Browse this author | | Okamoto, Michinari Browse this author | | Sawaya, Ryosuke Browse this author | | Kobayashi, Hiroyuki Browse this author | | Terasaka, Shunsuke Browse this author | | Houkin, Kiyohiro Browse this author |
| Keywords: | bevacizumab | | cytoreductive surgery | | glioblastoma multiforme | | recurrence |
| Issue Date: | Apr-2021 |
| Publisher: | Japan Neurosurgical Society |
| Journal Title: | Neurologia medico-chirurgica |
| Volume: | 61 |
| Issue: | 4 |
| Start Page: | 245 |
| End Page: | 252 |
| Publisher DOI: | 10.2176/nmc.oa.2020-0308 |
| Abstract: | Bevacizumab (BEV) is a key anti-angiogenic agent used in the treatment for recurrent glioblastoma multiforme (GBM). The aim of this study was to investigate whether cytoreductive surgery prior to treatment with BEV contributes to prolongation of survival for patients with recurrent GBM. We retrospectively analyzed the treatment outcomes of 124 patients with recurrent GBM who were initially treated with the Stupp protocol between 2006 and 2019. Given that BEV has only been available in Japan since 2013, we grouped the patients into two groups according to the time of first recurrence: the pre-BEV group (N = 51) included patients who had recurrence before BEV approval, and the BEV group (N = 73) included patients with recurrence after BEV approval. The overall survival after first recurrence (OS-R) was analyzed according to the treatment strategy. Among 124 patients, 27 patients (19.4%) received cytoreductive surgery. There were nine cases in the pre-BEV group and 18 cases in the BEV group. Although the mean extent of resection for both groups was almost equal, OS-R was significantly different. The median OS-R was 8.1 m in the pre-BEV group and 16.3 m in the BEV group (P = 0.007). Multivariate analysis revealed that the unavailability of BEV postoperatively (P = 0.03) and decreasing performance status by surgery (P = 0.01) were significant poor prognostic factors for survival after surgery. With the advent of BEV, cytoreductive surgery might provide superior survival benefit at the time of GBM recurrence, especially in cases where surgery can be performed without deteriorating the patient's condition. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/82138 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
